drugset
drugset / Trial / NCT01143779

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

NCT01143779 ↗

Phase 1 Completed 3 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if an imaging solution, \[F-18\]-fluoro-L-thymidine (FLT), when used with a positron emission tomography (PET) scan, can help doctors to better see changes in the growth of tumors in the body. Researchers want to learn if FLT-PET scans can show an early response to chemotherapy.

Timeline

Start
2010-06
Primary completion
2021-12-27
Completion
2021-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject [F-18]-fluoro-L-thymidine Diagnostic / imaging agent — Intravenous

Indications

No indication recorded.